Cancer Vaccines (Industry News)

Companies Announce Broad Antibody Development Agreement

Published in Vaccine Weekly, January 12th, 2000

Medarex, Inc., and IDM, a privately held European biotechnology company, announced the formation of a collaboration involving the use of Medarex's HuMAb-Mouse^TM technology for the generation of fully human antibodies.

In addition, IDM has also become Medarex's first partner for CTLA-4 Blockade technology to enhance cancer vaccines. IDM intends to pursue an anti-CTLA-4 approach in conjunction with its proprietary Dendritophages^TM as a cellular vaccine for the treatment of melanoma and prostate cancers.

"Medarex has a unique platform of powerful antibody technologies," stated Jean-Loup Romet-Lemonne, IDM. "This synergistic...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2000-01-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry